Skip to content

Epidemiology of Non-syndromic Dominant Deafness

Genetic Epidemiology of Non-syndromic Dominant Deafness

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01150305
Acronym
SURDOM
Enrollment
183
Registered
2010-06-24
Start date
2009-04-30
Completion date
2012-04-30
Last updated
2013-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Impairment

Keywords

Autosomal dominant inheritance, Mutation, Prevalence

Brief summary

Hearing impairment is a common disorder that affects at least 7% of individuals in our countries. Even the causes of hearing impairment are numerous, genetic causes represent the main factor of sensorineural deafness. Among hereditary non-syndromic deafness autosomal-dominant inheritance is observed in about 10-20% of the cases. These forms of deafness are usually post-lingual and progressive. To date more than 41 chromosomal localisation and 21 genes associated to non syndromic dominant deafness have been described. It represents an extreme genetic heterogeneity making difficult the studies of these forms of hearing impairment. But, genetic diagnostic testing is crucial in these cases. Indeed, therapeutic research are in the way to prevent the progression of the disorder. The aim of this work is to establish the prevalence of the different genes involved in these forms of deafness.

Detailed description

The protocol consists first in the recruitment of 150 families with non syndromic dominant hearing impairment. The families will be recruited by the clinical investigators. The clinic and radiological characteristics of the hearing impairment will be collected by the clinical investigators. Samples of patients and healthy relatives will be sent to the referral center. A linkage study of the whole genome by SNP studies is in progress in a cohort of large families affected by autosomal dominant deafness. This work will enable us to select the loci that may be frequently implicated in our population and screen these genes in the 150 families included in the protocol.

Interventions

BIOLOGICALblood sample

Peripheral whole blood sample, 5 ml

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \> 4 years. * Patient presenting familial dominant non syndromic hearing loss starting between 4 and 40 years old, over 2 generations * Healthy volunteer from the same families * Clinical and paraclinical assessment (genetic and ophthalmologic examination, audiometric tests, inner ear CT scan) * Affiliated to the national health insurance benefit * Signature of informed consent form

Exclusion criteria

* hearing loss resulting from an extrinsic reason or an associated syndrome * Defective or insufficient samples * No or insufficient clinical and biological description * No informed consent form

Design outcomes

Primary

MeasureTime frame
The identification of a deleterious mutation of a gene coding a protein present in the cochlea1 day

Secondary

MeasureTime frame
The phenotype genotype relationships after identification of the causative gene and mutation1 day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026